Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of osimertinib-first versus dacomitinib-first EGFR-TKI sequencing in EGFR-mutated advanced NSCLC
2024-518223-29-00Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib first with Dacomitinib first (2 arms). Primary endpoint: Overall survival. Planned start Mar 2020; status: authorised.
02
Drugs
osimertinibdacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518223-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518223-29-00.